Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.
Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.